Clinical Trial Details
| Trial ID: | L2840 |
| Source ID: | NCT00541567 |
| Associated Drug: | Ibipinabant |
| Title: | BMS-646256 in Obese and Overweight Type 2 Diabetics |
| Acronym: | |
| Status: | WITHDRAWN |
| Study Results: | NO |
| Results: | |
| Conditions: | Obesity and Type 2 Diabetes |
| Interventions: | DRUG: ibipinabant |
| Outcome Measures: | Primary: Absolute change from baseline in body weight (kg) and HbA1c (%), 26 weeks of double-blind therapy | Secondary: Waist circumference, fasting glucose and insulin, HOMA analysis, blood lipids (triglycerides, total cholesterol, HDL-C, LDL-C, ApoB) and systolic/ diastolic blood pressure, 52 weeks treatment followed by 20 weeks off-medication period |
| Sponsor/Collaborators: | Sponsor: Solvay Pharmaceuticals | Collaborators: Bristol-Myers Squibb |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2|PHASE3 |
| Enrollment: | 600 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT |
| Start Date: | 2008-03 |
| Completion Date: | 2010-06 |
| Results First Posted: | |
| Last Update Posted: | 2008-01-09 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT00541567 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|